Results hosted on duckduckgo.com
EMCDDA technical report on the new psychoactive substance N,Ndiethyl- 2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole- 1-ethanamine (isotonitazene)
New report provides window onto EU drug market changes during COVID-19
Meeting on the risk assessment of the new psychoactive substance isotonitazene
EMCDDA special report: COVID-19 and drugs – Drug supply via darknet markets
EMCDDA initial report on the new psychoactive substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene)
EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive substances
Reitox Baltic academy 'New Psychoactive Substances, Fentanils and their derivatives'
CEPOL training course 20/2019 Synthetic drugs and new psychoactive substances
Reitox national academy 'Online drug purchases and implications for health responses'
EU Drug Markets Report 2019
Video: EU Drug Markets Report 2019 - highlights
Infographic: new psychoactive substances (NPS) overview — substances reported to the EU Early Warning System since 1997
New report highlights wide-ranging impacts of EU drug markets on health and security
Highlights from the EU Drug Markets Report for policy and practice
New psychoactive substances: challenges for drug surveillance, control, and public health responses
2nd International Scientific School "Novel Psychoactive substances: focus on Novel Synthetic Opioids"
12th Annual Meeting of the Expert Group on the Prevention of Drug Precursors' Diversion
Serbia — Early warning system profile
Infographic: number and categories of new psychoactive substances notified to the EU Early Warning System for the first time, 2005-18
Infographic: Seizures reported to the EU Early Warning System: trends in total number of seizures and number of seizures by category in 2017